# Comparison of DTaP-IPV-Hep B-PRP~T Combined Vaccine to CombAct-HIB® Concomitantly Given With Engerix B® Paediatric and OPV

> **NCT00362336** · PHASE3 · COMPLETED · sponsor: **Sanofi Pasteur, a Sanofi Company** · enrollment: 622 (actual)

## Conditions studied

- Hepatitis B
- Polio
- Diphtheria
- Pertussis
- Haemophilus Influenzae Type b

## Interventions

- **BIOLOGICAL:** DTaP-IPV-HB-PRP~T
- **BIOLOGICAL:** CombAct-HIB®
- **BIOLOGICAL:** Engerix B® Pediatric

## Key facts

- **NCT ID:** NCT00362336
- **Lead sponsor:** Sanofi Pasteur, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-08
- **Primary completion:** 2008-05
- **Final completion:** 2009-08
- **Target enrollment:** 622 (ACTUAL)
- **Last updated:** 2014-05-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00362336

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00362336, "Comparison of DTaP-IPV-Hep B-PRP~T Combined Vaccine to CombAct-HIB® Concomitantly Given With Engerix B® Paediatric and OPV". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT00362336. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*